Multiple System Atrophy (MSA)

Multiple system atrophy (MSA) is particularly aggressive form of autonomic dysfunction. It has a rapidly progressive course and eventually is fatal. As with most chronic disease there is no cure. Unfortunately there are no proven therapies to delay progression of the disease. Currently established care is limited to symptom relief.

microglial cell

Microglia are the inflammatory cells of the nervous system. MSC therapy has proven top reduce the number of these cells in patients with MSA.

MSA is considered a neurodegenerative disorder. Microglia, which are the inflammatory cells of the nervous system, have been implicated in the progression of MSA. Based on this we have developed a treatment aimed at inhibition of microglia. Low Dose Naltrexone (LDN) is an oral medication that blocks the toll like receptor (TLR4) leading to microglia inhibition. LDN is an integral aspect of our treatment program for dysautonomia.

Stem cells are a promising new treatment option for MSA. A randomized trial of mesenchymal stem cells (MSC) demonstrated delay in progression of MSA1. We are currently studying the use of MSC for patients with MSA.


Learn About the Procedure Request Consultation

If you are a patient or know someone with MSA and are interested in more information on treatment options at Autonomic Specialists, please contact us toll free at (844) 247-2728 or (949) 247-8877.

1 http://www.ncbi.nlm.nih.gov/pubmed/22829267

Proud Members of: